These images show staining of a cell proliferation marker (Ki-67) in tumors after treatment with a placebo (left) or an estrogen-receptor degrader and a PRMT5 inhibitor (right).
Chang-Ching "Albert" Lin, Ph.D., is Assistant Professor in the Harold C. Simmons Comprehensive Cancer Center and in the Department of Internal Medicine at UT Southwestern.